Industry News

News Powered By:

- a collaborative partner.


Pfizer, Gamida Cell ink investment and option agreement

CenterWatch News Online Headlines : August 20, 2014 8:31 am : Centerwatch

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

BARDA extends contract with Cytori for thermal burn treatment

CenterWatch News Online Headlines : August 20, 2014 8:29 am : Centerwatch

Cytori Therapeutics, a California-based developer of cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions, and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, have announced the execution of a contract option to fund the continued investigation and development of Cytori Cell Therapy for use in thermal burn injuries.

RTI International develops novel lung-on-a-chip

CenterWatch News Online Headlines : August 20, 2014 8:27 am : Centerwatch

Researchers at RTI International, a nonprofit organization headquartered in Research Triangle Park, N.C., that provides research and technical services, in collaboration with the University of North Carolina at Chapel Hill, have developed a new lung-on-chip microdevice for laboratory studies of respiratory challenges and therapeutics. The microdevice includes multiple vertically stacked cellular layers that mimic the structure of the airway tissue. 

Valeant extends offer to acquire Allergan

CenterWatch News Online Headlines : August 20, 2014 8:26 am : Centerwatch

Valeant Pharmaceuticals International has extended the expiration of its exchange offer to acquire all outstanding shares of Allergan to 5:00 p.m., New York City time, Dec. 31. The exchange offer previously was scheduled to expire at 5:00 p.m., New York City time, Friday, Aug. 15. All other terms and conditions of the exchange offer remain unchanged.

MMS Holdings, Oncology Trials Insights partner on oncology support services

CenterWatch News Online Headlines : August 20, 2014 8:24 am : Centerwatch

MMS Holdings, a Mississippi-based global CRO that focuses on regulatory submission support, and Oncology Trials Insights (OTI), a Colorado-based organization of oncology key opinion leaders that architect superior clinical trial strategies and facilitate improved decision-making, have partnered to deliver comprehensive oncology support services.

« Page 1, 2, 3385 »